Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) \>/= 27 kg/m2~* HbA1c between 7.5% and 10.5% (inclusive)~* C-Peptide (fasting) greater than or equal to 500 pmol/L~* On stable dose of metformin alone or in combination with a stable dose of sulfonylurea for \>/= 3 months prior to screening, and remain on stable dose throughout the study~* Agree to conduct home-based (fasted) blood glucose testing as directed~Exclusion Criteria:~* Clinically significant abnormalities in medical history or physical exam~* Serum creatinine \> ULN at Screening~* Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT or AST \> 1.5x ULN at Screening~* History of renal transplantation or renal dialysis~* GFR \< 60 mL/min at Screening~* History of diabetic ketoacidosis~* History of greater than 3 episodes of severe hypoglycemia within 6 months of screening~* Allergy to sulfur containing drugs~* Treatment with other drugs or medications not allowed per study specific Disallowed Concomitant Medicines~* Any other significant illness or condition that may interfere with the patient participating or completing the study~* Inability or unwillingness to comply with protocol or study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ISIS-PTP1BRx (Type: EXPERIMENTAL): Weekly Dosing for 26 Weeks
- Placebo (Type: PLACEBO_COMPARATOR): Weekly Dosing for 26 Weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).